Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mohsen Aksoun"'
Autor:
Balsam Qubais Saeed, Farhad Jadidi-Niaragh, Fatemeh Aghakhani, Navneet Joshi, Lis M. Yapanto, Kazem Abbaszadeh-Goudarzi, Angelina Olegovna Zekiy, Mohsen Aksoun, Maryam Nasr Esfahani, Vahid Karpisheh, Shahin Hallaj, Vida Hashemi, Ata Mahmoodpoor, Sanam Dolati, Mahsa Movahed, Majid Ahmadi, Armin Mahmoud Salehi Khesht, Mohsen Nabi Afjadi
Publikováno v:
International Immunopharmacology
In various pathological conditions, cellular immunity plays an important role in immune responses. Among immune cells, T lymphocytes pdomote cellular and humoral responses as well as innate immunity. Therefore, careful investigation of these cells ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b3ddf95187932bbaeaa0c8b33afe4fa
https://pubmed.ncbi.nlm.nih.gov/34091116
https://pubmed.ncbi.nlm.nih.gov/34091116
Autor:
Farnaz Hajizadeh, Mohsen Aksoun, Behzad Beyzai, Farhad Jadidi-Niaragh, Mohammad Hojjat-Farsangi, Farzaneh Beigi Dargani, Angelina Olegovna Zekiy, Ali Masjedi
Publikováno v:
International immunopharmacology. 90
Oncostatin M (OSM), as a member of the Interleukin-6 family cytokines, plays a significant role in inflammation, autoimmunity, and cancers. It is mainly secreted by T lymphocytes, neutrophils, and macrophages and was initially introduced as anti-canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8de401d020ba6f16fa185b4c51a230bc
https://pubmed.ncbi.nlm.nih.gov/33187910
https://pubmed.ncbi.nlm.nih.gov/33187910
Autor:
Surendar Aravindhan, Fariba Karoon Kiani, Shima Bastaki, Afshin Nikkhoo, Simin Namvar Aghdash, Aleksei Evgenievich Dorofeev, Majid Ahmadi, Ata Mahmoodpoor, Ali Masjedi, Sanam Dolati, Mohsen Aksoun, Nasrin Ahmadpour Saheb, Hediyeh Jahandideh, Mahsa Afsari Kashani, Farzaneh Beigi Dargani, Farhad Jadidi-Niaragh
Publikováno v:
Life Sciences. 266:118847
Immunotherapy methods using potential tumor microenvironment modulators have elicited durable therapeutic responses in cancer treatment. Immune checkpoint molecule programmed cell death-ligand 1 (PD-L1) and oncogenic transcription factor STAT3 (signa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aed622f5ba3cb02041ee4ae632bd0479
https://doi.org/10.1016/j.lfs.2020.118847
https://doi.org/10.1016/j.lfs.2020.118847